Publicacións nas que colabora con Ferrán Navarro Risueño (26)

2023

  1. Corrigendum: CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3(Front. Microbiol., (2022), 13, (918362), 10.3389/fmicb.2022.918362)

    Frontiers in Microbiology

  2. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis

    The Lancet Regional Health - Europe, Vol. 34

2022

  1. CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

    Frontiers in Microbiology, Vol. 13

2020

  1. Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae

    Microbial Genomics, Vol. 6, Núm. 5, pp. 1-18

  2. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens

    Scientific Reports, Vol. 10, Núm. 1

  3. Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 182-187

2018

  1. Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop

    Microbial Drug Resistance, Vol. 24, Núm. 5, pp. 527-533

2017

  1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  2. Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results from the INCREMENT Cohort

    Clinical Infectious Diseases, Vol. 65, Núm. 10, pp. 1615-1623

  3. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

  4. Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC β-lactamases and/or carbapenemases in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 8, pp. 487-492

2016

  1. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  2. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

2015

  1. Mobile genetic elements related to the diffusion of plasmid-mediated AmpC β-lactamases or carbapenemases from enterobacteriaceae: Findings from a multicenter study in Spain

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 9, pp. 5260-5266

  2. Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain

    International Journal of Antimicrobial Agents, Vol. 46, Núm. 2, pp. 157-163

  3. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 6, pp. 3406-3412

  4. Rates of faecal colonization by carbapenemase-producing enterobacteriaceae among patients admitted to ICUs in Spain

    Journal of Antimicrobial Chemotherapy

2014

  1. Genetic and kinetic characterization of the novel AmpC β-lactamases DHA-6 and DHA-7

    Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 11, pp. 6544-6549

  2. Inhibitor-resistant TEM- And OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates

    Antimicrobial Agents and Chemotherapy, Vol. 58, Núm. 7, pp. 3874-3881

2013

  1. Characterization of the new AmpC β-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 Loop that affects ceftazidime hydrolysis

    Antimicrobial Agents and Chemotherapy, Vol. 57, Núm. 10, pp. 5158-5161